The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.

Inclusion Criteria:

• Over 18 years old.
• Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment.
• ECOG performance status of 0-2 and Karnofsky Score of 100-70.

Exclusion Criteria:

• Patients who have more effective therapy available than single agent docetaxel for the malignancy.
• Pregnancy or lactation.
• Intolerance to any antineoplastic agents belonging to the taxoid family.
• Hypersensitivity to drugs formulated with polysorbate 80.
• Active infection.
• Prior anticancer therapy within 30 days prior to the first day of study treatment.
• Participation in another experimental drug study within 30 days prior to the first day of study treatment.